ReviewCureus2025
Epidemiology, Pathogenesis, and Treatment Options of Monkeypox: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic variability and immunological aspects involved in response to MPXV infection.Frontiers in pharmacology · 2025Review
- Evaluating the advancements and efficacies in pharmacological Mpox treatments: a comprehensive review.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, human mpox (monkeypox) has emerged as a global outbreak. This debilitating disease is the result of a zoonotic infection and often entails multiorgan involvement. The knowledge of pathophysiology and treatment options is evolving. This review aims to summarise the pathophysiology and current treatment options of mpox. Prevention and vaccination strategies are out of the scope of this review. We performed a literature review to achieve this objective. Mpox is a zoonotic infection caused by the monkeypox virus, a double-stranded DNA virus. The virus, with debilitating complications, affects multiorgan functions, including skin and other systems. The available treatments for this widespread infection are limited. Only a few antivirals have been sanctioned and approved by the regulatory authorities. We have summarised the efficacy and safety of the three antiviral agents, namely, cidofovir (CDV), brincidofovir (BDV), and tecovirimat. The available limited evidence points towards promising efficacy and tolerability of tecovirimat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.